nodes	percent_of_prediction	percent_of_DWPC	metapath
Cisatracurium Besylate—Hypoxemia—Gemcitabine—pancreatic cancer	0.0725	0.0725	CcSEcCtD
Cisatracurium Besylate—Myopathy—Erlotinib—pancreatic cancer	0.0299	0.0299	CcSEcCtD
Cisatracurium Besylate—Myopathy—Sunitinib—pancreatic cancer	0.0259	0.0259	CcSEcCtD
Cisatracurium Besylate—Cardiovascular disorder—Tamoxifen—pancreatic cancer	0.0241	0.0241	CcSEcCtD
Cisatracurium Besylate—Cardiovascular disorder—Erlotinib—pancreatic cancer	0.0238	0.0238	CcSEcCtD
Cisatracurium Besylate—Hypoxia—Gemcitabine—pancreatic cancer	0.0229	0.0229	CcSEcCtD
Cisatracurium Besylate—Injury—Tamoxifen—pancreatic cancer	0.0167	0.0167	CcSEcCtD
Cisatracurium Besylate—Injury—Irinotecan—pancreatic cancer	0.0118	0.0118	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Sunitinib—pancreatic cancer	0.0116	0.0116	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Irinotecan—pancreatic cancer	0.0112	0.0112	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Gemcitabine—pancreatic cancer	0.0109	0.0109	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Erlotinib—pancreatic cancer	0.0103	0.0103	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Irinotecan—pancreatic cancer	0.0103	0.0103	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Fluorouracil—pancreatic cancer	0.00987	0.00987	CcSEcCtD
Cisatracurium Besylate—Flushing—Tamoxifen—pancreatic cancer	0.00987	0.00987	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Erlotinib—pancreatic cancer	0.00948	0.00948	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Sunitinib—pancreatic cancer	0.00927	0.00927	CcSEcCtD
Cisatracurium Besylate—Erythema—Tamoxifen—pancreatic cancer	0.00926	0.00926	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Fluorouracil—pancreatic cancer	0.00916	0.00916	CcSEcCtD
Cisatracurium Besylate—Erythema—Erlotinib—pancreatic cancer	0.00916	0.00916	CcSEcCtD
Cisatracurium Besylate—Bronchospasm—Gemcitabine—pancreatic cancer	0.00898	0.00898	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Sunitinib—pancreatic cancer	0.00895	0.00895	CcSEcCtD
Cisatracurium Besylate—Angioedema—Tamoxifen—pancreatic cancer	0.00846	0.00846	CcSEcCtD
Cisatracurium Besylate—Flushing—Sunitinib—pancreatic cancer	0.00845	0.00845	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Sunitinib—pancreatic cancer	0.00826	0.00826	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Sunitinib—pancreatic cancer	0.00823	0.00823	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Sunitinib—pancreatic cancer	0.00821	0.00821	CcSEcCtD
Cisatracurium Besylate—Hypertension—Tamoxifen—pancreatic cancer	0.00799	0.00799	CcSEcCtD
Cisatracurium Besylate—Erythema—Sunitinib—pancreatic cancer	0.00793	0.00793	CcSEcCtD
Cisatracurium Besylate—Cardiovascular disorder—Epirubicin—pancreatic cancer	0.00793	0.00793	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—pancreatic cancer	0.00774	0.00774	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Irinotecan—pancreatic cancer	0.00764	0.00764	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Irinotecan—pancreatic cancer	0.00737	0.00737	CcSEcCtD
Cisatracurium Besylate—Cardiovascular disorder—Doxorubicin—pancreatic cancer	0.00733	0.00733	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Erlotinib—pancreatic cancer	0.00733	0.00733	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Erlotinib—pancreatic cancer	0.00726	0.00726	CcSEcCtD
Cisatracurium Besylate—Angioedema—Sunitinib—pancreatic cancer	0.00724	0.00724	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Gemcitabine—pancreatic cancer	0.00718	0.00718	CcSEcCtD
Cisatracurium Besylate—Flushing—Irinotecan—pancreatic cancer	0.00696	0.00696	CcSEcCtD
Cisatracurium Besylate—Convulsion—Sunitinib—pancreatic cancer	0.00687	0.00687	CcSEcCtD
Cisatracurium Besylate—Hypertension—Sunitinib—pancreatic cancer	0.00684	0.00684	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Irinotecan—pancreatic cancer	0.00681	0.00681	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Irinotecan—pancreatic cancer	0.00678	0.00678	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Irinotecan—pancreatic cancer	0.00676	0.00676	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Tamoxifen—pancreatic cancer	0.00673	0.00673	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—pancreatic cancer	0.0067	0.0067	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Erlotinib—pancreatic cancer	0.00666	0.00666	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Gemcitabine—pancreatic cancer	0.00663	0.00663	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Gemcitabine—pancreatic cancer	0.0066	0.0066	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Gemcitabine—pancreatic cancer	0.00659	0.00659	CcSEcCtD
Cisatracurium Besylate—Bronchospasm—Docetaxel—pancreatic cancer	0.00637	0.00637	CcSEcCtD
Cisatracurium Besylate—Erythema—Gemcitabine—pancreatic cancer	0.00636	0.00636	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Sunitinib—pancreatic cancer	0.00634	0.00634	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Sunitinib—pancreatic cancer	0.00628	0.00628	CcSEcCtD
Cisatracurium Besylate—Erythema—Fluorouracil—pancreatic cancer	0.00625	0.00625	CcSEcCtD
Cisatracurium Besylate—Urticaria—Tamoxifen—pancreatic cancer	0.006	0.006	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Sunitinib—pancreatic cancer	0.00577	0.00577	CcSEcCtD
Cisatracurium Besylate—Hypertension—Irinotecan—pancreatic cancer	0.00564	0.00564	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Tamoxifen—pancreatic cancer	0.00557	0.00557	CcSEcCtD
Cisatracurium Besylate—Hypertension—Gemcitabine—pancreatic cancer	0.00549	0.00549	CcSEcCtD
Cisatracurium Besylate—Convulsion—Fluorouracil—pancreatic cancer	0.00542	0.00542	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.00538	0.00538	CcSEcCtD
Cisatracurium Besylate—Pruritus—Tamoxifen—pancreatic cancer	0.00534	0.00534	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Irinotecan—pancreatic cancer	0.00533	0.00533	CcSEcCtD
Cisatracurium Besylate—Pruritus—Erlotinib—pancreatic cancer	0.00529	0.00529	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Irinotecan—pancreatic cancer	0.00523	0.00523	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Epirubicin—pancreatic cancer	0.00522	0.00522	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Gemcitabine—pancreatic cancer	0.00519	0.00519	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Fluorouracil—pancreatic cancer	0.0051	0.0051	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Docetaxel—pancreatic cancer	0.0051	0.0051	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Gemcitabine—pancreatic cancer	0.00509	0.00509	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Gemcitabine—pancreatic cancer	0.00504	0.00504	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Fluorouracil—pancreatic cancer	0.00501	0.00501	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Fluorouracil—pancreatic cancer	0.00498	0.00498	CcSEcCtD
Cisatracurium Besylate—Hypotension—Irinotecan—pancreatic cancer	0.00498	0.00498	CcSEcCtD
Cisatracurium Besylate—Hypotension—Gemcitabine—pancreatic cancer	0.00485	0.00485	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Doxorubicin—pancreatic cancer	0.00483	0.00483	CcSEcCtD
Cisatracurium Besylate—Flushing—Docetaxel—pancreatic cancer	0.00481	0.00481	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Epirubicin—pancreatic cancer	0.00481	0.00481	CcSEcCtD
Cisatracurium Besylate—Hypotension—Fluorouracil—pancreatic cancer	0.00477	0.00477	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Sunitinib—pancreatic cancer	0.00477	0.00477	CcSEcCtD
Cisatracurium Besylate—Rash—Tamoxifen—pancreatic cancer	0.00476	0.00476	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Tamoxifen—pancreatic cancer	0.00476	0.00476	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Irinotecan—pancreatic cancer	0.00475	0.00475	CcSEcCtD
Cisatracurium Besylate—Rash—Erlotinib—pancreatic cancer	0.00471	0.00471	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Erlotinib—pancreatic cancer	0.00471	0.00471	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Docetaxel—pancreatic cancer	0.0047	0.0047	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Docetaxel—pancreatic cancer	0.00468	0.00468	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Docetaxel—pancreatic cancer	0.00467	0.00467	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Gemcitabine—pancreatic cancer	0.00463	0.00463	CcSEcCtD
Cisatracurium Besylate—Pruritus—Sunitinib—pancreatic cancer	0.00458	0.00458	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Fluorouracil—pancreatic cancer	0.00455	0.00455	CcSEcCtD
Cisatracurium Besylate—Erythema—Docetaxel—pancreatic cancer	0.00451	0.00451	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Epirubicin—pancreatic cancer	0.00446	0.00446	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Doxorubicin—pancreatic cancer	0.00445	0.00445	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Doxorubicin—pancreatic cancer	0.00413	0.00413	CcSEcCtD
Cisatracurium Besylate—Rash—Sunitinib—pancreatic cancer	0.00408	0.00408	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Sunitinib—pancreatic cancer	0.00408	0.00408	CcSEcCtD
Cisatracurium Besylate—Urticaria—Fluorouracil—pancreatic cancer	0.00405	0.00405	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Irinotecan—pancreatic cancer	0.00393	0.00393	CcSEcCtD
Cisatracurium Besylate—Convulsion—Docetaxel—pancreatic cancer	0.00391	0.00391	CcSEcCtD
Cisatracurium Besylate—Hypertension—Docetaxel—pancreatic cancer	0.0039	0.0039	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.00382	0.00382	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Fluorouracil—pancreatic cancer	0.00376	0.00376	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Docetaxel—pancreatic cancer	0.00368	0.00368	CcSEcCtD
Cisatracurium Besylate—Pruritus—Gemcitabine—pancreatic cancer	0.00367	0.00367	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Docetaxel—pancreatic cancer	0.00361	0.00361	CcSEcCtD
Cisatracurium Besylate—Pruritus—Fluorouracil—pancreatic cancer	0.00361	0.00361	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Docetaxel—pancreatic cancer	0.0036	0.0036	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Docetaxel—pancreatic cancer	0.00358	0.00358	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Epirubicin—pancreatic cancer	0.00356	0.00356	CcSEcCtD
Cisatracurium Besylate—Hypotension—Docetaxel—pancreatic cancer	0.00344	0.00344	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Epirubicin—pancreatic cancer	0.00344	0.00344	CcSEcCtD
Cisatracurium Besylate—Rash—Irinotecan—pancreatic cancer	0.00336	0.00336	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Irinotecan—pancreatic cancer	0.00336	0.00336	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Doxorubicin—pancreatic cancer	0.00329	0.00329	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Docetaxel—pancreatic cancer	0.00328	0.00328	CcSEcCtD
Cisatracurium Besylate—Rash—Gemcitabine—pancreatic cancer	0.00327	0.00327	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Gemcitabine—pancreatic cancer	0.00327	0.00327	CcSEcCtD
Cisatracurium Besylate—Flushing—Epirubicin—pancreatic cancer	0.00325	0.00325	CcSEcCtD
Cisatracurium Besylate—Rash—Fluorouracil—pancreatic cancer	0.00322	0.00322	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Fluorouracil—pancreatic cancer	0.00322	0.00322	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.00318	0.00318	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Epirubicin—pancreatic cancer	0.00317	0.00317	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Epirubicin—pancreatic cancer	0.00316	0.00316	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Epirubicin—pancreatic cancer	0.00315	0.00315	CcSEcCtD
Cisatracurium Besylate—Erythema—Epirubicin—pancreatic cancer	0.00304	0.00304	CcSEcCtD
Cisatracurium Besylate—Flushing—Doxorubicin—pancreatic cancer	0.003	0.003	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Doxorubicin—pancreatic cancer	0.00294	0.00294	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Doxorubicin—pancreatic cancer	0.00292	0.00292	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.00292	0.00292	CcSEcCtD
Cisatracurium Besylate—Erythema—Doxorubicin—pancreatic cancer	0.00282	0.00282	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Docetaxel—pancreatic cancer	0.00271	0.00271	CcSEcCtD
Cisatracurium Besylate—Convulsion—Epirubicin—pancreatic cancer	0.00264	0.00264	CcSEcCtD
Cisatracurium Besylate—Hypertension—Epirubicin—pancreatic cancer	0.00263	0.00263	CcSEcCtD
Cisatracurium Besylate—Pruritus—Docetaxel—pancreatic cancer	0.00261	0.00261	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.00257	0.00257	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Epirubicin—pancreatic cancer	0.00248	0.00248	CcSEcCtD
Cisatracurium Besylate—Convulsion—Doxorubicin—pancreatic cancer	0.00244	0.00244	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Epirubicin—pancreatic cancer	0.00244	0.00244	CcSEcCtD
Cisatracurium Besylate—Hypertension—Doxorubicin—pancreatic cancer	0.00243	0.00243	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Epirubicin—pancreatic cancer	0.00243	0.00243	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Epirubicin—pancreatic cancer	0.00241	0.00241	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.00238	0.00238	CcSEcCtD
Cisatracurium Besylate—Rash—Docetaxel—pancreatic cancer	0.00232	0.00232	CcSEcCtD
Cisatracurium Besylate—Hypotension—Epirubicin—pancreatic cancer	0.00232	0.00232	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Docetaxel—pancreatic cancer	0.00232	0.00232	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.0023	0.0023	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Doxorubicin—pancreatic cancer	0.00225	0.00225	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Doxorubicin—pancreatic cancer	0.00224	0.00224	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Doxorubicin—pancreatic cancer	0.00223	0.00223	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Epirubicin—pancreatic cancer	0.00222	0.00222	CcSEcCtD
Cisatracurium Besylate—Hypotension—Doxorubicin—pancreatic cancer	0.00215	0.00215	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Doxorubicin—pancreatic cancer	0.00205	0.00205	CcSEcCtD
Cisatracurium Besylate—Urticaria—Epirubicin—pancreatic cancer	0.00197	0.00197	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Epirubicin—pancreatic cancer	0.00183	0.00183	CcSEcCtD
Cisatracurium Besylate—Urticaria—Doxorubicin—pancreatic cancer	0.00183	0.00183	CcSEcCtD
Cisatracurium Besylate—Pruritus—Epirubicin—pancreatic cancer	0.00176	0.00176	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Doxorubicin—pancreatic cancer	0.00169	0.00169	CcSEcCtD
Cisatracurium Besylate—Pruritus—Doxorubicin—pancreatic cancer	0.00163	0.00163	CcSEcCtD
Cisatracurium Besylate—Rash—Epirubicin—pancreatic cancer	0.00157	0.00157	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Epirubicin—pancreatic cancer	0.00157	0.00157	CcSEcCtD
Cisatracurium Besylate—Rash—Doxorubicin—pancreatic cancer	0.00145	0.00145	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Doxorubicin—pancreatic cancer	0.00145	0.00145	CcSEcCtD
